• Browse
• Mon inscription (Login)
• Inscription (gratuite)

•  
•  
•  
•  
•  
•  

This section contains news related to the pharmaceutique industry.

Publishers of pharmaceutique related news can register for free on our website and add their pharmaceutique news to this website.

Pharmaceutical News

• Lawsuits Help Ensure Drug Safety, NEJM Editors Say
  Wed, 20 August 2008
  FDA by itself cannot guarantee drug safety and state-level lawsuits are a vital deterrent to help protect consumers against drugmakers that do not disclose all risks associated with a treatment, editors of the New England Journal of Medicine wrote in a friend-of-the-court brief on Thursday, the
• ProPublica Examines U.S. Investigation Into Pharmaceutical Company Ranbaxy Over Antiretr ...
  Wed, 20 August 2008
  ProPublica on Thursday examined a U.S. investigation into whether Indian pharmaceutical company Ranbaxy engaged in a pattern of systemic fraudulent conduct by concealing its drug manufacturing process violated FDA standards, including HIV/AIDS medications used in the
• Logical Therapeutics Inc. Announces Results Of Phase 1b Clinical Study Of Its Naproxen P ...
  Tue, 19 August 2008
  Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced the successful completion of its Phase 1b randomized controlled multi-dose safety and pharmacokinetics study of LT-NS001, the Company's proprieta ...
• Bioniche Phase III Clinical Trial In Bladder Cancer Progressing Well
  Tue, 19 August 2008
  Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced that its first Phase III clinical trial with a formulation of Mycobacterial Cell Wall-DNA Complex (MCC), trademarked Urocidin, for the treatment of bladder cancer, is progress ...
• Oxford Researchers Give Protein Production More Precision
  Tue, 19 August 2008
  Oxford researchers have developed a new technique to prepare proteins for use as therapeutic drugs. The technology, which represents a significant step forward from current production methods, will enable the development of purer and more effective protein-based drugs. Therapeutic proteins are currently prescribed fo ...
• Restrictions On The Import Of Unlicensed Melatonin Products Following The Grant Of A Mar ...
  Tue, 19 August 2008
  Dear Healthcare Professional, Restrictions on the import of unlicensed Melatonin products following the grant of a marketing authorisation for Circadin 2mg tablets At the beginning of June 2008, a licensed modified release melatonin product, Circadin (Lundbeck), became available in the UK.
• Industry Experts And Global Regulators To Discuss Oligonucleotide-Based Therapeutics Issues
  Mon, 18 August 2008
  The Drug Information Association (DIA), in collaboration with the FDA, Oligonucleotide Therapeutics Society, Health Canada, and the American Association of Pharmaceutical Scientists, will host the 2nd Conference on Oligonucleotide-based Therapeutics (September 22 - 24; Falls Church, VA).
• New Report Examines How To Launch A Medicine Or A Product In French Pharmacies
  Mon, 18 August 2008
  Research and Markets has announced the addition of the Launching a Medicine or a Product in French Pharmacies report to their offering. Many foreign companies would like to sell their products, medicinal or not, to French pharmacies but do not know how about doing so.
• An In-depth Insight Into The Partnering Interests And Activities Of Takeda Partnering Gu ...
  Mon, 18 August 2008
  Research and Markets has announced the addition of the Takeda Partnering Guide 2008 company profile to their offering. This report provides all the information you require to better understand Takeda and its partnering interests and activities over the past five years.
• Genentech Special Committee Of Independent Directors Responds To Roche Proposal
  Mon, 18 August 2008
  The special committee of the Board of Directors of Genentech, Inc. (NYSE:DNA) announced that, after careful consideration, it has unanimously concluded that Roche's proposal to acquire the shares of Genentech not owned by Roche for 89.00 per share substantially undervalues the company. Therefore, the special committee does n ...